Pro Bono Bio has acquired and developed proprietary technologies to create new medical devices and drug and protein management solutions.
- Unique core disruptive technology platforms and IP; Sequessomes, Tethersomes, Chaperones and Transfersomes
- Proprietary technology developed at a cost of over $250m
- Specific proprietary product technologies protected by patents and patent applications giving cover for more than 15 years
- Over 2000 people in over 20 successful clinical trials with products